Vaccines are in vogue and practically taunting pharma with the potential of blockbuster price tags. But while big companies reign in the sector—largely due to cost- and resource-related barriers of entry—a handful of smaller players are taking a stab at creating vaccines for a narrowing field of unmet diseases, like RSV and C. diff. Rebecca Mayer Knutsen reports
from Most popular articles from Medical Marketing and Media http://ift.tt/1L5eSWk
No comments:
Post a Comment